Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
vitreous detachment/protease
Veza se sprema u međuspremnik
9 rezultati
[Enzymatically induced posterior vitreous detachment in proliferative diabetic vitreoretinopathy].
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND
Complete detachment of the posterior vitreous cortex is an important aim in the treatment of proliferative diabetic vitreoretinopathy (PDVR). Today a posterior vitreous detachment (PVD) can only be achieved during vitrectomy. A randomized pilot study was started to evaluate wether
Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE
To investigate the effects of intravitreal injection of nattokinase (subtilisin NAT), a serine protease that is produced by Bacillus subtilis (natto), for induction of posterior vitreous detachment (PVD).
METHODS
Different doses of nattokinase (1, 0.1, or 0.01 fibrin-degradation units
[Research update of ocriplasmin for symptomatic vitreomacular adhesion].
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Ocriplasmin is a recombinant truncated form of human serine protease plasmin with proteolytic activity to induce vitreous liquefaction and weaken vitreomacular adhesion, thereby facilitating posterior vitreous detachment and acting as a potential alternative to replace the more traumatic vitrectomy
Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE
In angiogenesis, matrix degradation is an important step in endothelial cell migration and proliferation. There is evidence that serine proteases, such as tissue plasminogen activator (TPA), urokinase-type plasminogen activator (UPA), and plasminogen activator inhibitor (PAI), are involved
From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND
Pharmacologic vitreolysis is a strategy used to treat anomalous posterior vitreous detachment, by weakening vitreoretinal adhesion with an intravitreal drug. Pharmacologic vitreolysis facilitates surgery, and abnormalities of the vitreoretinal interface including vitreomacular traction
Assessment of Ocriplasmin Effects on the Vitreoretinal Compartment in Porcine and Human Model Systems.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Ocriplasmin (Jetrea®) is a recombinant protease used to treat vitreomacular traction. To gain insight into vitreoretinal observations reported after ocriplasmin treatment, we have developed an in vivo porcine ocriplasmin-induced posterior vitreous detachment (PVD) model in which we investigated
Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Ocriplasmin (JETREA(®)) is a recombinant human serine protease plasmin with proteolytic activity against the protein components (e.g. laminin, fibronectin and collagen) of the vitreous and vitreoretinal interface, thereby facilitating vitreous liquefaction and separation of vitreous from the retina.
Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
With increased knowledge about the origins and pathophysiology of vitreo-retinal disorders—and, in particular, the central role of anomalous posterior vitreous detachment in vitreo-maculopathies—a paradigm shift from surgery to pharmacotherapy is taking place with the development of pharmacologic
Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND
Vitreomacular adhesion can lead to pathologic traction and macular hole. The standard treatment for severe, symptomatic vitreomacular adhesion is vitrectomy. Ocriplasmin is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal
Najkompletnija baza ljekovitog bilja potpomognuta naukom
- Radi na 55 jezika
- Biljni lijekovi potpomognuti naukom
- Prepoznavanje biljaka po slici
- Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
- Pročitajte naučne publikacije povezane sa vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima
